Friday, May 29
Health

ASCO News: Bristol and Pfizer report favorable results — Day 1

No Comments2 Mins Read
ASCO News: Bristol and Pfizer report favorable results — Day 1

Chicago, where thousands in the cancer world gather each year.Adam Feuerstein/STAT

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Matthew Herper covers medical innovation — both its promise and its perils.

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08.

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here.  

We’re ASCOmaxxing.

Rest assured, this will not require Adam Feuerstein, Matthew Herper or Angus Chen to hammer on their jawlines. They will, however, be scouring the ASCO annual meeting to bring you the cancer news, analysis and event coverage you crave.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

  2. Senior Writer, Medicine, Editorial Director of Events

See also  Green Wedding Ideas For A Memorable Eco-Friendly Celebration
Share.

Related Posts

Add A Comment

Leave A Reply